Rowachol for Gallstone Treatment
Rowachol is not recommended for the treatment of cholesterol gallstones, as it actually worsens bile composition by significantly lowering cholesterol solubility rather than improving it. 1
Evidence Against Rowachol Use
The only available clinical evidence on Rowachol demonstrates harmful effects on bile chemistry:
Rowachol at a dose of 2 capsules three times daily for 48 hours significantly deteriorated cholesterol solubility in both gallbladder bile (P < 0.001) and T-tube bile (P < 0.05), making bile more lithogenic rather than therapeutic. 1
Higher doses (4 capsules four times daily) caused even more significant deterioration in biliary lipid composition (P < 0.05). 1
Lower doses (1 capsule three times daily) showed no effect on bile composition, offering no therapeutic benefit. 1
Recommended Treatment Alternatives for Cholesterol Gallstones <1.5 cm
First-Line: Ursodeoxycholic Acid (Ursodiol)
For patients who are poor surgical candidates with small (<1.5 cm), radiolucent cholesterol stones, ursodeoxycholic acid at 8-10 mg/kg/day is the evidence-based medical therapy. 2, 3, 4
Complete stone dissolution occurs in approximately 30% of unselected patients with uncalcified gallstones <20 mm treated for up to 2 years. 4
Dissolution rates increase to 50% in patients with floating or floatable stones (high cholesterol content). 4
Stones up to 5 mm in diameter achieve 81% complete dissolution. 4
Treatment requires 3 weeks to reach steady-state bile acid concentrations and typically 6-24 months for complete dissolution. 4
Patient Selection Criteria for Bile Acid Therapy
Only 20% of cholecystectomy patients are suitable candidates for oral bile acid therapy: 2
Stones must be radiolucent (cholesterol-rich) on imaging. 2, 5
Stone diameter must be <1.5 cm (preferably <6 mm for optimal results). 2, 5
Gallbladder must be patent with functioning cystic duct (demonstrated by oral cholecystography opacification). 5
Stones should be floating or floatable for best outcomes. 3, 4
Alternative Non-Surgical Options
For solitary radiolucent stones <2 cm, extracorporeal shock-wave lithotripsy (ESWL) combined with adjuvant oral bile acids achieves approximately 80% success for single stones. 3, 5
Multiple stones (n<3) have lower success rates of approximately 40%. 5
ESWL breaks stones into fragments that are then dissolved by oral bile acid therapy. 2
Critical Limitations and Pitfalls
Stone Recurrence
Gallstone recurrence occurs in approximately 50% of patients within 5 years after successful dissolution with any medical therapy. 4, 5
Recurrence cannot be reliably prevented by low-dose bile acid maintenance or dietary modifications. 5
Medical Therapy Will Not Prevent
Future gallbladder cancer risk (unlike cholecystectomy). 2, 3
Need for eventual intervention in many patients. 3
Predictors of Treatment Failure
Development of gallbladder nonvisualization during treatment predicts failure and warrants discontinuation. 4
Calcified stones or stones developing calcification during treatment rarely dissolve. 4
Stones >20 mm in diameter have minimal dissolution rates. 4
Surgical Consideration
Laparoscopic cholecystectomy remains the gold standard for symptomatic gallstones with >95% success rate and >97% completion rate, offering definitive cure without recurrence risk. 3, 6